Elsalys Biotech SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Elsalys Biotech SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11275
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Elsalys Biotech SA (Elsalys Biotech) is a pharmaceutical company that develops new generation antibodies to modulate the immune system of patients with cancer or rare haematological diseases. The company’s pipeline programs include anti-CD160, for macular degeneration or certain retinopathies; anti-CD160, for solid tumors and blood cancer; anti-Tyro3, for solid tumors; and anti-S100b, for idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. It also develops Leukotac, an immunotherapy antibody developed for the treatment of orphan disease with very poor prognosis: steroid-resistant acute graft versus host disease. Elsalys Biotech’s specialization spans from target sourcing to the pre-industrial production of drug candidates. The company works in collaboration with academic and other industry partners to conduct programs, clinical evaluation of antibody candidates and to develop immune-based therapies. Elsalys Biotech is headquartered in Lyon, France.

Elsalys Biotech SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Elsalys Biotech SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 10
ElsaLys Biotech Acquires Rights of Anti-CD160 Antibody from MabLife 11
Venture Financing 12
ElsaLys Biotech Raises Additional USD3 Million in Financing Round 12
ElsaLys Biotech Raises US$2.7 Million In First Round Of Financing 13
Licensing Agreements 15
Laboratoires Thea Enters into Licensing Option Agreement with Elsalys Biotech 15
Elsalys Biotech Enters into Licensing Agreement with Transgene 16
ElsaLys Biotech Enters into Licensing Agreement with Inserm Transfert 17
Equity Offering 18
Elsalys Biotech Files Registration Statement to Raise Funds in IPO 18
Acquisition 19
Transgene Acquires 37% Stake in ElsaLys Biotech 19
Elsalys Biotech SA – Key Competitors 20
Elsalys Biotech SA – Key Employees 21
Elsalys Biotech SA – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Corporate Communications 23
Jan 30, 2017: Elsalys Biotech expands its team to strengthen its strategy and the development of its programs 23
Product News 25
04/05/2018: Elsalys Biotech: LEUKOTAC takes next step in paediatric acute steroid-resistant GvHD 25
03/15/2018: EUKOTAC at the 44th Congress of the European Society for Blood and Marrow Transplantation (EBMT) 26
Clinical Trials 27
Jul 18, 2017: ELSALYS BIOTECH and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Key Facts 2
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Elsalys Biotech SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Elsalys Biotech SA, Deals By Therapy Area, 2012 to YTD 2018 8
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 10
ElsaLys Biotech Acquires Rights of Anti-CD160 Antibody from MabLife 11
ElsaLys Biotech Raises Additional USD3 Million in Financing Round 12
ElsaLys Biotech Raises US$2.7 Million In First Round Of Financing 13
Laboratoires Thea Enters into Licensing Option Agreement with Elsalys Biotech 15
Elsalys Biotech Enters into Licensing Agreement with Transgene 16
ElsaLys Biotech Enters into Licensing Agreement with Inserm Transfert 17
Elsalys Biotech Files Registration Statement to Raise Funds in IPO 18
Transgene Acquires 37% Stake in ElsaLys Biotech 19
Elsalys Biotech SA, Key Competitors 20
Elsalys Biotech SA, Key Employees 21
Elsalys Biotech SA, Other Locations 22

List of Figures
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Elsalys Biotech SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Verbund AG:企業の発電所・SWOT分析2018
    Verbund AG - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executi …
  • Sinclair Oil Corporation:企業の戦略・SWOT・財務情報
    Sinclair Oil Corporation - Strategy, SWOT and Corporate Finance Report Summary Sinclair Oil Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Multan Electric Power Company:企業の戦略的SWOT分析
    Multan Electric Power Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • R1 RCM Inc (RCM):企業の財務・戦略的SWOT分析
    R1 RCM Inc (RCM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • PolyNovo Biomaterials Pty Ltd:企業の製品パイプライン分析2018
    Summary PolyNovo Biomaterials Pty Ltd (PolyNovo), a subsidiary of PolyNovo Ltd is a medical technology company that develops, designs and manufactures controlled bioeroding tissue and orthopedic solutions. The company’s Novosorb polymers are based on polyurethanes, a polymer family used in medical a …
  • Clark Construction Group LLC:企業の戦略的SWOT分析
    Clark Construction Group LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Wotif.com Holdings Limited:企業の戦略・SWOT・財務分析
    Wotif.com Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Wotif.com Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Rolls-Royce Holdings Plc:企業のM&A・事業提携・投資動向
    Rolls-Royce Holdings Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Rolls-Royce Holdings Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Tandem Diabetes Care Inc (TNDM):企業の製品パイプライン分析
    Summary Tandem Diabetes Care Inc (Tandem) is a medical device manufacturing company that designs and develops diabetic care products. The company's product portfolio includes t:slim X2 insulin pump, basal-IQ technology, software and applications, infusion sets and other pump accessories. It also pro …
  • The Master Trust Bank of Japan, Ltd.:企業のM&A・事業提携・投資動向
    The Master Trust Bank of Japan, Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Master Trust Bank of Japan, Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports …
  • University of Bath:製薬・医療:M&Aディール及び事業提携情報
    Summary University of Bath (UOB) is an educational institution that provides educational and research services. The institute provides under graduate and post graduate programs in the fields of science, engineering and design, humanities and social sciences, and management studies. It also conducts …
  • Parexel International Corp:医療機器:M&Aディール及び事業提携情報
    Summary Parexel International Corp (Parexel) is a biopharmaceutical outsourcing service company which focuses on providing various services for managing the biopharmaceutical product lifecycle and for the development and commercialization of new medical therapies. It offers a comprehensive range of …
  • Miragen Therapeutics Inc (MGEN):製薬・医療:M&Aディール及び事業提携情報
    Summary Miragen Therapeutics, Inc. (Miragen) is a clinical stage biopharmaceutical company. It discovers and develops RNA-targeted therapeutics with a focus on microRNAs and their role in diseases. The company is developing its pipeline products for the treatment of Cutaneous T-Cell Lymphoma (CTCL), …
  • Cegid Group SA (CGD):企業の財務・戦略的SWOT分析
    Cegid Group SA (CGD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Tata Power Solar Systems Ltd:企業の戦略的SWOT分析
    Tata Power Solar Systems Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Biotest AG (BIO)-製薬・医療分野:企業M&A・提携分析
    Summary Biotest AG (Biotest) is a provider of pharmaceutical and biotherapeutic drugs which develops, manufactures and distributes biological medicines through its value chain from preclinical and clinical development to sales. Its main products comprise clotting factors, immunoglobulins, albumin an …
  • Depuy Synthes Companies:企業の戦略・SWOT・財務分析
    Depuy Synthes Companies - Strategy, SWOT and Corporate Finance Report Summary Depuy Synthes Companies - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Shibuya Kogyo Co., Ltd.:企業の戦略・SWOT・財務情報
    Shibuya Kogyo Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shibuya Kogyo Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Ceconomy AG (CEC):企業の財務・戦略的SWOT分析
    Ceconomy AG (CEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Enercon Services Inc:電力:M&Aディール及び事業提携情報
    Summary Enercon Services, Inc. (Enercon) is a diversified consulting company offering architectural engineering, environmental, technical and management services. Its offerings include licensing, operations, permitting, construction, decommissioning, and staff augmentation, cyber security and regula …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆